Cover Image
Market Research Report
Product code 
1075532

Glioblastoma Multiforme Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Published: | Transparency Market Research | 101 Pages | Delivery time: 1-2 business days

Price

Back to Top
Glioblastoma Multiforme Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028
Published: March 29, 2022
Transparency Market Research
Content info: 101 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Glioblastoma Multiforme Treatment (GBM) Market - Scope of Report

TMR's report on the global glioblastoma multiforme treatment (GBM) market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global glioblastoma multiforme treatment (GBM) market for the period 2017-2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global glioblastoma multiforme treatment (GBM) market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global glioblastoma multiforme treatment (GBM) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global glioblastoma multiforme treatment (GBM) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global glioblastoma multiforme treatment (GBM) market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global glioblastoma multiforme treatment (GBM) market.

The report delves into the competitive landscape of the global glioblastoma multiforme treatment (GBM) market. Key players operating in the global glioblastoma multiforme treatment (GBM) market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global glioblastoma multiforme treatment (GBM) market that have been profiled in this report.

Key Questions Answered in Glioblastoma Multiforme Treatment (GBM) Market Report

What is the scope of growth of product companies in the global glioblastoma multiforme treatment (GBM) market?

What will be the Y-o-Y growth of the global glioblastoma multiforme treatment (GBM) market between 2017 and 2028?

What is the influence of changing trends in technologies on the global glioblastoma multiforme treatment (GBM) market?

Will North America be the most profitable market for glioblastoma multiforme treatment (GBM) providers?

Which factors are anticipated to hamper the growth of the global glioblastoma multiforme treatment (GBM) market during the forecast period?

Which are the leading companies in the global glioblastoma multiforme treatment (GBM) market?

Research Methodology

TMR has utilized a unique research methodology to conduct comprehensive research on the growth of the global glioblastoma multiforme treatment (GBM) market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global glioblastoma multiforme treatment (GBM) market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the glioblastoma multiforme treatment (GBM) market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the glioblastoma multiforme treatment (GBM) market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global glioblastoma multiforme treatment (GBM) market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on future prospects of the global glioblastoma multiforme treatment (GBM) market more reliably and accurately.

Product Code: TMRGL4807

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Glioblastoma Multiforme Treatment (GBM) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, 2017-2028

5. Key Insights

  • 5.1. Regulatory Scenario, by Region/globally
  • 5.2. Key Mergers & Acquisitions
  • 5.3. Technological Advancements
  • 5.4. COVID-19 Pandemics Impact on Industry

6. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Treatment

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Treatment, 2017-2028
    • 6.3.1. Radiation Therapy
    • 6.3.2. Chemotherapy
      • 6.3.2.1. Temozolomide
      • 6.3.2.2. Bevacizumab
      • 6.3.2.3. Carmustine
      • 6.3.2.4. Other Types of Chemotherapy
    • 6.3.3. Other Treatments
  • 6.4. Market Attractiveness Analysis, by Treatment

7. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by End-user, 2017-2028
    • 7.3.1. Hospitals
    • 7.3.2. Ambulatory Surgical Centers
    • 7.3.3. Clinics
  • 7.4. Market Attractiveness Analysis, By End-user

8. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, By Country/Region

9. North America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Treatment, 2017-2028
    • 9.2.1. Radiation Therapy
    • 9.2.2. Chemotherapy
      • 9.2.2.1. Temozolomide
      • 9.2.2.2. Bevacizumab
      • 9.2.2.3. Carmustine
      • 9.2.2.4. Other Types of Chemotherapy
  • 9.3. Market Value Forecast, by End-user, 2017-2028
    • 9.3.1. Hospitals
    • 9.3.2. Ambulatory Surgical Centers
    • 9.3.3. Clinics
  • 9.4. Market Value Forecast, by Country, 2017-2028
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Treatment
    • 9.5.2. By End-user
    • 9.5.3. By Country

10. Europe Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment, 2017-2028
    • 10.2.1. Radiation Therapy
    • 10.2.2. Chemotherapy
    • 10.2.3. Temozolomide
    • 10.2.4. Bevacizumab
    • 10.2.5. Carmustine
    • 10.2.6. Other Types of Chemotherapy
    • 10.2.7. Other Treatments
  • 10.3. Market Value Forecast, by End-user, 2017-2028
    • 10.3.1. Hospitals
    • 10.3.2. Ambulatory Surgical Centers
    • 10.3.3. Clinics
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2028
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Treatment
    • 10.5.2. By End-user
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment, 2017-2028
    • 11.2.1. Radiation Therapy
    • 11.2.2. Chemotherapy
      • 11.2.2.1. Temozolomide
      • 11.2.2.2. Bevacizumab
      • 11.2.2.3. Carmustine
      • 11.2.2.4. Other Types of Chemotherapy
    • 11.2.3. Other Treatments
  • 11.3. Market Value Forecast, by End-user, 2017-2028
    • 11.3.1. Hospitals
    • 11.3.2. Ambulatory Surgical Centers
    • 11.3.3. Clinics
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2028
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment
    • 11.5.2. By Drug Class
    • 11.5.3. By End-user
    • 11.5.4. By Country/Sub-region

12. Latin America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment, 2017-2028
    • 12.2.1. Radiation Therapy
    • 12.2.2. Chemotherapy
      • 12.2.2.1. Temozolomide
      • 12.2.2.2. Bevacizumab
      • 12.2.2.3. Carmustine
      • 12.2.2.4. Other Types of Chemotherapy
    • 12.2.3. Other Treatments
  • 12.3. Market Value Forecast, by End-user, 2017-2028
    • 12.3.1. Hospitals
    • 12.3.2. Ambulatory Surgical Centers
    • 12.3.3. Clinics
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2028
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment
    • 12.5.2. By Drug Class
    • 12.5.3. By End-user
    • 12.5.4. By Country/Sub-region

13. Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment, 2017-2028
    • 13.2.1. Radiation Therapy
    • 13.2.2. Chemotherapy
      • 13.2.2.1. Temozolomide
      • 13.2.2.2. Bevacizumab
      • 13.2.2.3. Carmustine
      • 13.2.2.4. Other Types of Chemotherapy
    • 13.2.3. Other Treatments
  • 13.3. Market Value Forecast, by End-user, 2017-2028
    • 13.3.1. Hospitals
    • 13.3.2. Ambulatory Surgical Centers
    • 13.3.3. Clinics
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2028
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Treatment
    • 13.5.2. By Drug Class
    • 13.5.3. By End-user
    • 13.5.4. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (by tier and size of companies)
  • 14.2. Market Share Analysis, by Company, 2020
  • 14.3. Company Profiles
    • 14.3.1. Merck & Co., Inc.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Financial Analysis
      • 14.3.1.3. Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. F. Hoffmann-La Roche Ltd.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Financial Analysis
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Pfizer Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Financial Analysis
      • 14.3.3.3. Growth Strategies
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Amgen, Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Financial Analysis
      • 14.3.4.3. Growth Strategies
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Teva Pharmaceutical Industries Ltd.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Financial Analysis
      • 14.3.5.3. Growth Strategies
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. Sun Pharmaceutical Industries Ltd.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Financial Analysis
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Arbor Pharmaceuticals, LLC
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Financial Analysis
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Amneal Pharmaceuticals
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Financial Analysis
      • 14.3.8.3. Growth Strategies
      • 14.3.8.4. SWOT Analysis
    • 14.3.9. Karyopharm Therapeutics, Inc.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Financial Analysis
      • 14.3.9.3. Growth Strategies
      • 14.3.9.4. SWOT Analysis
    • 14.3.10. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Financial Analysis
      • 14.3.10.3. Growth Strategies
      • 14.3.10.4. SWOT Analysis

List of Tables

TABLE 1: Market Snapshot: Global Glioblastoma Multiforme Treatment (GBM) Market

TABLE 2: Global Prevalence of Glioblastoma Multiforme worldwide

TABLE 3: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017-2031

TABLE 4: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017-2031

TABLE 5: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Geography, 2017-2031

TABLE 6: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country, 2017-2031

TABLE 7: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017-2031

TABLE 8: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017-2031

TABLE 9: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017-2031

TABLE 10: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017-2031

TABLE 11: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017-2031

TABLE 12: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017-2031

TABLE 13: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017-2031

TABLE 14: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017-2031

TABLE 15: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017-2031

TABLE 16: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017-2031

TABLE 17: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017-2031

TABLE 18: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017-2031

TABLE 19: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017-2031

TABLE 20: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017-2031

List of Figures

FIG. 1: Comparative Analysis: Global 3D Printing Market, by Treatment, 2021 & 2028 (%)

FIG. 2: Global Glioblastoma Multiforme Treatment (GBM) Market Segmentation

FIG. 3: Global Glioblastoma Multiforme Treatment (GBM) Market, by Drug Class, 2020

FIG. 4: Global Glioblastoma Multiforme Treatment (GBM) Market, by Treatment, 2020

FIG. 5: Global Glioblastoma Multiforme Treatment (GBM) Market: Drivers and Restraints

FIG. 6: Porter's Five Forces Analysis for Glioblastoma Multiforme Treatment (GBM) Market

FIG. 7: Market Attractiveness Analysis: Glioblastoma Multiforme Treatment (GBM) Market, by Region

FIG. 8: Global Glioblastoma Multiforme Treatment (GBM) Market Share Analysis of Key Players

FIG. 9: Global Glioblastoma Multiforme Treatment (GBM) Market Segmentation, by Drug Class

FIG. 10: Global Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021-2028

FIG. 11: Global Radiation Therapy Market Value (US$ Mn), 2021-2028

FIG. 12: Global Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 13: Global Temozolomide Market Value (US$ Mn), 2021-2028

FIG. 14: Global Bevacizumab Market Value (US$ Mn), 2021-2028

FIG. 15: Global Lomustine Market Value (US$ Mn), 2021-2028

FIG. 16: Global Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 17: Global Tumor Treating Field (TTF) Therapy Market, 2021-2028

FIG. 18: Market Segmentation of Glioblastoma Multiforme Treatment (GBM) Market, by Drug Class

FIG. 19: North America Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021-2028

FIG. 20: North America Radiation Therapy Market Value (US$ Mn), 2021-2028

FIG. 21: North America Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 22: North America Temozolomide Market Value (US$ Mn), 2021-2028

FIG. 23: North America Bevacizumab Market Value (US$ Mn), 2021-2028

FIG. 24: North America Lomustine Market Value (US$ Mn), 2021-2028

FIG. 25: North America Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 26: North America Tumor Treating Field (TTF) Therapy Market, 2021-2028

FIG. 27: Europe Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021-2028

FIG. 28: Europe Radiation Therapy Market Value (US$ Mn), 2021-2028

FIG. 29: Europe Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 30: Europe Temozolomide Market Value (US$ Mn), 2021-2028

FIG. 31: Europe Bevacizumab Market Value (US$ Mn), 2021-2028

FIG. 32: Europe Lomustine Market Value (US$ Mn), 2021-2028

FIG. 33: Europe Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 34: Europe Tumor Treating Field (TTF) Therapy Market, 2021-2028

FIG. 35: Asia Pacific Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021-2028

FIG. 36: Asia Pacific Radiation Therapy Market Value (US$ Mn), 2021-2028

FIG. 37: Asia Pacific Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 38: Asia Pacific Temozolomide Market Value (US$ Mn), 2021-2028

FIG. 39: Asia Pacific Bevacizumab Market Value (US$ Mn), 2021-2028

FIG. 40: Asia Pacific l Lomustine Market Value (US$ Mn), 2021-2028

FIG. 41: Asia Pacific Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 42: Asia Pacific Tumor Treating Field (TTF) Therapy Market, 2021-2028

FIG. 43: Latin America Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021-2028

FIG. 44: Latin America Radiation Therapy Market Value (US$ Mn), 2021-2028

FIG. 45: Latin America Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 46: Latin America Temozolomide Market Value (US$ Mn), 2021-2028

FIG. 47: Latin America Bevacizumab Market Value (US$ Mn), 2021-2028

FIG. 48: Latin America Lomustine Market Value (US$ Mn), 2021-2028

FIG. 49: Latin America Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 50: Latin America Tumor Treating Field (TTF) Therapy Market, 2021-2028

FIG. 51: Middle East & Africa Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021-2028

FIG. 52: Middle East & Africa Radiation Therapy Market Value (US$ Mn), 2021-2028

FIG. 53: Middle East & Africa Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 54: Middle East & Africa Temozolomide Market Value (US$ Mn), 2021-2028

FIG. 55: Middle East & Africa Bevacizumab Market Value (US$ Mn), 2021-2028

FIG. 56: Middle East & Africa Lomustine Market Value (US$ Mn), 2021-2028

FIG. 57: Middle East & Africa Targeted Therapy Market Value (US$ Mn), 2021-2028

FIG. 58: Middle East & Africa Tumor Treating Field (TTF) Therapy Market, 2021-2028